Published in Gene Therapy Weekly, July 6th, 2000
"We developed a practical allogeneic tumor cell vaccine for the immuno-gene therapy of colon cancer based on the immunologic profiles of established colon carcinoma cell lines compared to fresh colon carcinoma cultures," announced Daniel L. Shawler and colleagues from Sidney Kimmel Cancer Center and Immune Response Corporation, California. "The vaccine consists of three established cell lines, SW620, COLO 205, and SW403, that are HLA-A2 positive; do not secrete high levels of the immunosuppressive factors TGF-(beta)1 and -(beta)2, interleukin...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.